JAGOTEC AG s/ Jacques Gonella ------------------- by: by: its: its:
JAGOTEC AG a Swiss corporation having its place of business at Xxxxxxxxxxxxxxx 0 0, XX-0 000 Xxxxxxx, Xxxxxxxxxxx (hereinafter referred to as “Jagotec”);
JAGOTEC AG. By: /s/ Xxxxxxxxx Xxxxxxxx --------------------------------------- Name: Xxxxxxxxx Xxxxxxxx Position: Director JAGOTEC AG By: /s/ Xxxxxxx Halleisen --------------------------------------- Name: Xxxxxxx Halleisen Position: Director CRITICAL THERAPEUTICS, INC. By: /s/ Xxxx Xxxxx --------------------------------------- NAME: DR. XXXX XXXXX POSITION: PRESIDENT AND CHIEF EXECUTIVE OFFICER SCHEDULE 1 THE ZILEUTON REVISED PLAN AND TIMELINE [**] SCHEDULE 2 THE PATENTS [**]
JAGOTEC AG. By: /s/ Jacques Gonella --------------------- Dr. Jacques Gonella President ------------------ * Confidential treatment rexxxxxxx. Xxx xxdacted material has been separaxxxx xxxxx xxxh the Commission. JAGO PHARMA AG hereby agrees to be bound by the provisions of sections 2.2, 6.3, 11.2.4.2, 11.4.3, 11.4.5, and 11.5 and article 16 of the * Development and Marketing Agreement and sections 11.2.4.2 and 11.5 of the above Agreement, agrees that all notices to be given to it shall be given to such address as is set forth in section 16.1 hereof unless and until it otherwise instructs APOTHECON in writing: JAGO PHARMA AG By: /s/ Jacques Gonella --------------------- Dr. Jacques Gonella President
JAGOTEC AG s/ Jacques Gonella /s/ -------------------------- -------------------------- By: By: Its: Its:
JAGOTEC AG. 6 Amounts paid by Jagotec during the Year for Active Material in respect of Product deficiencies in accordance with Section 3.12 and Recalls in accordance with Section 8 of the Agreement. Per: Name: SCHEDULE 4
